Home » Stocks » EWTX

Edgewise Therapeutics, Inc. (EWTX)

Stock Price: $29.54 USD -0.46 (-1.53%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
Market Cap 1.41B
Revenue (ttm) n/a
Net Income (ttm) -17.12M
Shares Out 47.57M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $29.54
Previous Close $30.00
Change ($) -0.46
Change (%) -1.53%
Day's Open 30.04
Day's Range 28.94 - 31.00
Day's Volume 95,375
52-Week Range 25.09 - 40.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

1 week ago - Business Wire

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the ...

2 weeks ago - Business Wire

Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Edgewise Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About EWTX

Edgewise Therapeutics' vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combi... [Read more...]

Industry
Biotechnology
IPO Date
Mar 26, 2021
CEO
Kevin Koch, Ph.D.
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
EWTX
Full Company Profile

Financial Performance

Financial Statements